Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | TK2 | O00142 | 1/20 | 0.53 |
| ▸ | TYMS | P04818 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17283457 | 1.00 | TK1 (0.57) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL15066131 | 1.00 | TK1 (0.57) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL18873431 | 1.00 | TK1 (0.57) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL17279676 | 1.00 | TK1 (0.57) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL27093268 | 0.95 | TYMS (0.54) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL27094655 | 0.92 | TYMS (0.54) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL27093301 | 0.92 | TK1 (0.51) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL25387297 | 0.91 | TK1 (0.55) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL12112419 | 0.91 | LMNA (0.60) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL1311495 | 0.91 | LMNA (0.60) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10620210-B2 | Aptamers and diagnostic methods for detecting the EGF receptor | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2020-04-14 | — | — | US | claimed |
| EP-3335714-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | Quest Diagnostics Investments Incorporated (US) | 2018-06-20 | — | — | EP | claimed |
| US-20170328909-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2017-11-16 | — | — | US | claimed |
| US-9651556-B2 | Aptamers and diagnostic methods for detecting the EGF receptor | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2017-05-16 | — | — | US | claimed |
| US-12540330-B2 | Stem-loop compositions and methods for inhibiting vascular endothelial growth factor | DRIVE THERAPEUTICS LLC (US) | 2026-02-03 | — | — | US | disclosed |
| US-12534734-B2 | Stem-loop compositions and methods for inhibiting interleukin-8 | DRIVE THERAPEUTICS LLC (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250197868-A1 | COMPOSITIONS AND METHODS FOR INHIBITING FACTOR D | VITRISA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20240218374-A1 | Nucleic Acid Compounds That Bind Coronavirus Proteins | SOMALOGIC OPERATING CO., INC. (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4323524-A1 | NUCLEIC ACID COMPOUNDS THAT BIND CORONAVIRUS PROTEINS | SomaLogic Operating Co., Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-116783299-A | Bispecific aptamer compositions for the treatment of retinal diseases | 戴福医疗有限责任公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-4132540-A2 | BISPECIFIC APTAMER COMPOSITIONS FOR THE TREATMENT OF RETINAL DISORDERS | Drive Therapeutics L.L.C. (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3405577-B1 | COMPOSITIONS AND METHODS FOR INHIBITING FACTOR D | 396419 B C LTD (CA) | 2022-12-14 | — | — | EP | disclosed |
| US-9651556-B2 | Aptamers and diagnostic methods for detecting the EGF receptor | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2017-05-16 | — | — | US | disclosed |
| US-9316647-B2 | Aptamers and diagnostic methods for detecting the EGF receptor | SOMALOGIC, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150086996-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2015-03-26 | — | — | US | disclosed |
| EP-2797603-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | Somalogic, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2798085-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | Quest Diagnostics Investments Incorporated (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140296501-A1 | Aptamers and Diagnostic Methods for Detecting the EGF Receptor | SOMALOGIC OPERATING CO. INC. | 2014-10-02 | — | — | US | disclosed |
| WO-2013102096-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013102101-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | SOMALOGIC, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540330-B2 | Stem-loop compositions and methods for inhibiting vascular endothelial growth factor | KDR, VEGFA, FLT1 | TK1 272/4885LMNA 459/4885SMN1; SMN2 2924/4885 |
| US-20140296501-A1 | Aptamers and Diagnostic Methods for Detecting the EGF Receptor | EGFR, ERBB3, ERBB2 | TK1 693/4885LMNA 3541/4885SMN1; SMN2 4347/4885 |
| US-20250197868-A1 | COMPOSITIONS AND METHODS FOR INHIBITING FACTOR D | CFD, CFH, CFB | TK1 2843/4885LMNA 783/4885SMN1; SMN2 2961/4885 |
| US-12534734-B2 | Stem-loop compositions and methods for inhibiting interleukin-8 | CXCL8, CCR8, CXCR1 | TK1 606/4885LMNA 1488/4885SMN1; SMN2 3575/4885 |
| US-20240218374-A1 | Nucleic Acid Compounds That Bind Coronavirus Proteins | SARS1, RNGTT, PABPC1 | TK1 1812/4885LMNA 1529/4885SMN1; SMN2 4641/4885 |
| US-20170328909-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | EGFR, ERBB2, ERBB3 | TK1 187/4885LMNA 2108/4885SMN1; SMN2 4617/4885 |
| US-10620210-B2 | Aptamers and diagnostic methods for detecting the EGF receptor | EGFR, ERBB2, ERBB3 | TK1 187/4885LMNA 2108/4885SMN1; SMN2 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.